This study looks at how well a drug called **iptacopan** works over a long time in people with **C3 glomerulopathy (C3G)** or **idiopathic immune-complex-membranoproliferative glomerulonephritis (IC-MPGN)**. These are conditions that affect the kidneys by causing inflammation and damage. Participants should have finished a previous treatment study. This study is open-label, meaning everyone knows they are taking iptacopan, and aims to see how safe and effective it is when taken for a long time.

• The study could last up to about 14 years.
• Participants will have several visits and continuous access to iptacopan.
• Risks include possible infections or heart problems, so not everyone can join.

To join, participants must have completed previous studies related to the drug. They cannot have serious heart or lung conditions, active infections, or a history of certain immune diseases. The study continues until the drug becomes available to the public, or if the drug's benefits don't outweigh the risks. Regular check-ups will help monitor the effects and safety of the treatment.